Long-term pregabalin treatment protects basal cortices and delays the occurrence of spontaneous seizures in the lithium-pilocarpine model in the rat

Epilepsia. 2003 Jul;44(7):893-903. doi: 10.1046/j.1528-1157.2003.61802.x.

Abstract

Purpose: To determine whether a pharmacologic treatment could delay or prevent the epileptogenesis induced by status epilepticus (SE) through the protection of some brain areas, we studied the effects of the long-term exposure to pregabalin (PGB) on neuronal damage and epileptogenesis induced by lithium-pilocarpine SE.

Methods: SE was induced in adult and 21-day-old (P21) rats. At 20 min after pilocarpine, rats received 50 mg/kg PGB (pilo-preg) or saline (pilo-saline). PGB treatment was given daily at the dose of 50 mg/kg for 7 days after SE and at 10 mg/kg from day 8 until killing. Neuronal damage was assessed in hippocampus and piriform and entorhinal cortices in brain sections stained with thionine and obtained from adult and P21 animals killed 6 days after SE. The number of glial fibrillary acidic protein (GFAP)-reactive astrocytes was tested by immunohistochemistry in sections adjacent to those used for cell counting. The latency to spontaneous seizures was controlled by visual observation and EEG recording.

Results: PGB induced neuroprotection in layer II of piriform cortex and layers III-IV of ventral entorhinal cortex of adult rats, whereas no hippocampal region was protected. In P21 rats, damage was limited to the hilus and similar in pilo-preg and pilo-saline animals. The number of GFAP-positive astrocytes was higher in pilocarpine- than in saline-treated rats. It was decreased in pilo-preg compared with pilo-saline rats in layer II of the piriform cortex. Adult pilo-preg rats became epileptic after a longer latency (39 days) than did pilo-saline rats (22 days).

Conclusions: These data underline the antiepileptogenic consequences of long-term PGB treatment, possibly mediated by the protection of piriform and entorhinal cortices in the lithium-pilocarpine model of epilepsy.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Anticonvulsants / pharmacology*
  • Astrocytes / drug effects
  • Astrocytes / pathology
  • Brain / drug effects*
  • Brain / pathology
  • Brain / physiopathology
  • Cell Death / drug effects*
  • Cell Death / physiology
  • Cerebral Cortex / drug effects
  • Cerebral Cortex / pathology
  • Cerebral Cortex / physiopathology
  • Convulsants
  • Electroencephalography / drug effects*
  • Entorhinal Cortex / drug effects
  • Entorhinal Cortex / pathology
  • Entorhinal Cortex / physiopathology
  • Epilepsy, Temporal Lobe / chemically induced
  • Epilepsy, Temporal Lobe / pathology
  • Epilepsy, Temporal Lobe / physiopathology*
  • Glial Fibrillary Acidic Protein / metabolism
  • Hippocampus / drug effects
  • Hippocampus / pathology
  • Hippocampus / physiopathology
  • Immunoenzyme Techniques
  • Lithium
  • Neuroprotective Agents / pharmacology*
  • Parahippocampal Gyrus / drug effects
  • Parahippocampal Gyrus / pathology
  • Parahippocampal Gyrus / physiopathology
  • Pilocarpine
  • Pregabalin
  • Rats
  • Rats, Sprague-Dawley
  • Status Epilepticus / chemically induced
  • Status Epilepticus / pathology
  • Status Epilepticus / physiopathology*
  • gamma-Aminobutyric Acid / analogs & derivatives*
  • gamma-Aminobutyric Acid / pharmacology*

Substances

  • Anticonvulsants
  • Convulsants
  • Glial Fibrillary Acidic Protein
  • Neuroprotective Agents
  • Pilocarpine
  • Pregabalin
  • gamma-Aminobutyric Acid
  • Lithium